Lutetium-177-labelled bombesin analogue

Drug Profile

Lutetium-177-labelled bombesin analogue

Alternative Names: 177Lu-AMBA

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bracco
  • Developer Bracco; Marillion Pharmaceuticals
  • Class Lanthanoid series elements; Peptide hormones
  • Mechanism of Action Bombesin receptor agonists; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Prostate-cancer in Europe (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer(Late-stage disease, Metastatic disease) in USA (IV)
  • 12 Nov 2008 Lutetium-177-labelled bombesin analogue licensed to Marillion Pharmaceuticals worldwide for the treatment of hormone-resistant prostate and metastatic breast cancers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top